**Background**
Cystic fibrosis (CF) is a severe genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR protein functions as a chloride channel across the epithelial cell membranes of various organs, including the lungs and pancreas. When the CFTR protein is dysfunctional or absent, it leads to the production of thick, sticky mucus, resulting in chronic pulmonary infections, progressive lung damage, and multi-organ failure. Developing small molecules that can correct the folding of the CFTR protein or potentiate its gating activity is a critical strategy for treating this disease. In this context, we will introduce a CFTR modulator – Olacaftor.
**Definition**
Olacaftor (VX-440) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. According to the Olacaftor description, this compound is designed to improve the function of the CFTR protein to alleviate the symptoms associated with cystic fibrosis.
**Mechanism of Action**
Olacaftor acts as a modulator of the CFTR channel, aiming to restore the transport of chloride ions across the cell membrane. By improving the stability and gating of the CFTR protein, it helps normalize the viscosity of mucus in the respiratory tract. Researchers seeking detailed Olacaftor technical information can refer to its chemical properties, including its molecular weight of 539.66 and its Olacaftor Formula, $\text{C}_{29}\text{H}_{34}\text{FN}_3\text{O}_4\text{S}$.
**Experimental Studies**
The Olacaftor biological activity has been characterized through extensive pharmacological evaluations. As detailed in the Olacaftor References, the compound was developed to target specific CFTR mutations to enhance protein trafficking and function. While specific IC50 values and detailed cell line concentrations are typically proprietary or specified in the patent documentation, the compound has been validated for its ability to modulate the CFTR protein. In conclusion, Olacaftor is a potent CFTR modulator that holds significant potential for the treatment of cystic fibrosis.
Keywords
Olacaftor, 1897384-89-2, VX-440, VX440, VX 440, CFTR, Autophagy, Cystic fibrosis transmembrane conductance regulator, Inhibitor, inhibitor, inhibit
References
[1] Miller M, et al. Modulators of cystic fibrosis transmembrane conductance regulator. US9782408.